Drugs / Cligabalin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07606820 | Oct 2025 → Oct 2026 expected | rosacea | The First Affiliated Hospital with Nanjing Medical University | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cligabalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07606820 ↗ |
| Known as | HSK16149 | “Cligabalin(HSK16149)20mg BID” NCT07606820 ↗ |
| Route | Oral | “Cligabalin（HSK16149） 20mg bid po for rosacea” NCT07606820 ↗ |